UB Paderborn / Katalog / Suche / in CDI

Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice

Clinical transplantation, 2014-02, Vol.28 (2), p.161-165

2014

Link zum Volltext

Verfügbarkeit prüfen

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

Journal of the European Academy of Dermatology and Venereology, 2014-05, Vol.28 (5), p.581-589

2014

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Journal of the European Academy of Dermatology and Venereology, 2015-02, Vol.29 (2), p.361-366

2015

Link zum Volltext

Verfügbarkeit prüfen

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Journal of the European Academy of Dermatology and Venereology, 2015-08, Vol.29 (8), p.1555-1561

2015

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

British journal of cancer, 2006-09, Vol.95 (5), p.581-586

2006

Link zum Volltext

Verfügbarkeit prüfen

The use of granulocyte colony-stimulating factors in a Canadian outpatient setting

Current oncology (Toronto), 2014-04, Vol.21 (2), p.e229-240

2014

Link zum Volltext

Verfügbarkeit prüfen

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

Current oncology (Toronto), 2019-12, Vol.26 (6), p.e748-754

2019

Link zum Volltext

Verfügbarkeit prüfen

Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Value in health, 2015-05, Vol.18 (3), p.A304-A305

2015

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Value in health, 2015-05, Vol.18 (3), p.A168-A168

2015

Link zum Volltext

Verfügbarkeit prüfen

THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.233-233

2016

Link zum Volltext

Verfügbarkeit prüfen

2132 Retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

European journal of cancer (1990), 2015-09, Vol.51, p.S376-S376

2015

Link zum Volltext

Verfügbarkeit prüfen

COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

Value in health, 2016-05, Vol.19 (3), p.A229-A230

2016

Link zum Volltext

Verfügbarkeit prüfen

AB0389 Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.659-659

2013

Link zum Volltext

Verfügbarkeit prüfen

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.240

2014

Link zum Volltext

Verfügbarkeit prüfen

FRI0161 Response to etanercept-methotrexate therapy and etanercept monotherapy in rheumatoid arthritis patients with moderate and severe disease in the cameo trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A425-A426

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparaison de l’augmentation de la dose et de l’intensification du traitement d’association chez les patients atteints de polyarthrite rhumatoïde qui amorcent un traitement biologique par l’étanercept, l’adalimumab et l’infliximab

Revue du rhumatisme (Ed. française : 1993), 2016-11, Vol.83, p.A187-A188

2016

Link zum Volltext

Verfügbarkeit prüfen

Différences de gravité du psoriasis chez des sujets atteints ou non de rhumatisme psoriasique et traités par l’étanercept

Annales de dermatologie et de vénéréologie, 2012-12, Vol.139 (12), p.B283-B284

2012

Link zum Volltext

Verfügbarkeit prüfen

Etiology of community-acquired pneumonia treated in an ambulatory setting

Respiratory medicine, 2005, Vol.99 (1), p.60-65

2005

Link zum Volltext

Verfügbarkeit prüfen

PSY74 - Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Value in health, 2015-05, Vol.18 (3), p.A304-A305

2015

Link zum Volltext

Verfügbarkeit prüfen

PMS88 - Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Value in health, 2015-05, Vol.18 (3), p.A168-A168

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-01

2018

Link zum Volltext

Verfügbarkeit prüfen

PMS29 - COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

Value in health, 2016-05, Vol.19 (3), p.A229-A230

2016

Link zum Volltext

Verfügbarkeit prüfen

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study: Table 1

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.240-240

2014

Link zum Volltext

Verfügbarkeit prüfen

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5036-5036

2007

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.LBA1-LBA1

2007

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

The use of granulocyte colony-stimulating factors in a Canadian outpatient setting

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment

2132 Retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

AB0389 Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study

FRI0161 Response to etanercept-methotrexate therapy and etanercept monotherapy in rheumatoid arthritis patients with moderate and severe disease in the cameo trial

Comparaison de l’augmentation de la dose et de l’intensification du traitement d’association chez les patients atteints de polyarthrite rhumatoïde qui amorcent un traitement biologique par l’étanercept, l’adalimumab et l’infliximab

Différences de gravité du psoriasis chez des sujets atteints ou non de rhumatisme psoriasique et traités par l’étanercept

Etiology of community-acquired pneumonia treated in an ambulatory setting

PSY74 - Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

PMS88 - Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

PMS29 - COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study: Table 1

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Aktive Filter

Suchergebnisse filtern